Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine and empagliflozin in reduced ejection fraction after myocardial infarction
IRCT20111206008307N39Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Feb 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of empagliflozin and colchicine in heart failure with reduced ejection fraction (HFrEF) and myocardial infarction (MI) (3 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: hs-CRP, NYHA Functional Classification and 2 more. Started Feb 2023; status: completed.
02
Drugs
empagliflozincolchicine
03
Conditions
heart failure with reduced ejection fraction (HFrEF)myocardial infarction (MI)
Beyond the preview
Go deeper on IRCT20111206008307N39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20111206008307N39.